Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer. This story matters for Finance & Markets readers tracking fund. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →